Ranbaxy puts biosimilars into gear

RANBAXY-BIOSIMILARS-LAUNCHES:Ranbaxy puts biosimilars into gear

 July 11, 2012, 3:23 IST

 07 11, 2012, 03:30 IST

 

Laboratories Ltd will launch at least three copies of biotech medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech drugs to remain a serious player in the global generics business, Chief Executive Arun Sawhney said on Tuesday.

Sawhney said that Ranbaxy, majority-owned by Japanese drugmaker Daiichi Sankyo <4568.T>, will introduce a "biosimilar" cancer treatment in India next year and follow up with at least two other in the same market over the following year or two.

The company's goal is to seek initial approval for all the drugs in India and then pursue approval within four to five years in Europe and the United States.

Like other biotech medicines, biosimilar drugs are made in living cells through a costly and time-consuming process. currently sells only one biosimilar, a copycat form of Amgen Inc's Neupogen, used to prevent infections following chemotherapy. The product is sold in India.

Sawhney said two of Ranbaxy's chief rivals, Israeli drugmaker Teva Pharmaceutical Industries and the Sandoz unit of Swiss drugmaker , already have expertise in biosimilars. hopes to eventually compete with them in the potentially lucrative business, he said.

The biosimilar plans to introduce in India next year, Sawhney said in an interview in New York, has the potential for global annual sales in the hundreds of millions of dollars.

"The attractiveness of biosimilars, regardless of the product, is you'll always have limited competition because of the complexity and the investments required" to make such medicines, he said.

Other drugmakers, including Merck & Co , are racing to develop even though the U.S. Food and Drug Administration has yet to announce formal guidelines for how biosimilar medicines should be tested and marketed. Europe has already released such guidelines.

"Of the top 10 drugs in the world, more than half are biotech drugs and probably seven of the top 10 will be by 2015. That tells us the importance of being present in the biosimilar space," Sawhney said. "If we want to remain a serious (industry) player, inherently we must be competitive."

Sawhney became chief executive in 2010, a year after the FDA forbade shipments to the United States of generic medicines made at two factories in India that were cited for quality-control lapses.

Shipments from the plants resumed in April, after agreed to terms of a consent decree with the FDA. It mandates quality-control inspections of the plants by an external auditor.

Chairman Tsutomu Une, also in an interview, said the quality-control issues - which largely involved poor documentation of procedures - were an embarassment for the Indian drugmaker.

"This must never happen again," said Une, who has a seat on Daiichi Sankyo's board of directors.

 

image
Business Standard
177 22
Business Standard

Ranbaxy puts biosimilars into gear

RANBAXY-BIOSIMILARS-LAUNCHES:Ranbaxy puts biosimilars into gear

Reuters  |  By Ransdell Pierson</p> 

 July 11, 2012, 3:23 IST

 07 11, 2012, 03:30 IST

 

Laboratories Ltd will launch at least three copies of biotech medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech drugs to remain a serious player in the global generics business, Chief Executive Arun Sawhney said on Tuesday.

Sawhney said that Ranbaxy, majority-owned by Japanese drugmaker Daiichi Sankyo <4568.T>, will introduce a "biosimilar" cancer treatment in India next year and follow up with at least two other in the same market over the following year or two.

The company's goal is to seek initial approval for all the drugs in India and then pursue approval within four to five years in Europe and the United States.

Like other biotech medicines, biosimilar drugs are made in living cells through a costly and time-consuming process. currently sells only one biosimilar, a copycat form of Amgen Inc's Neupogen, used to prevent infections following chemotherapy. The product is sold in India.

Sawhney said two of Ranbaxy's chief rivals, Israeli drugmaker Teva Pharmaceutical Industries and the Sandoz unit of Swiss drugmaker , already have expertise in biosimilars. hopes to eventually compete with them in the potentially lucrative business, he said.

The biosimilar plans to introduce in India next year, Sawhney said in an interview in New York, has the potential for global annual sales in the hundreds of millions of dollars.

"The attractiveness of biosimilars, regardless of the product, is you'll always have limited competition because of the complexity and the investments required" to make such medicines, he said.

Other drugmakers, including Merck & Co , are racing to develop even though the U.S. Food and Drug Administration has yet to announce formal guidelines for how biosimilar medicines should be tested and marketed. Europe has already released such guidelines.

"Of the top 10 drugs in the world, more than half are biotech drugs and probably seven of the top 10 will be by 2015. That tells us the importance of being present in the biosimilar space," Sawhney said. "If we want to remain a serious (industry) player, inherently we must be competitive."

Sawhney became chief executive in 2010, a year after the FDA forbade shipments to the United States of generic medicines made at two factories in India that were cited for quality-control lapses.

Shipments from the plants resumed in April, after agreed to terms of a consent decree with the FDA. It mandates quality-control inspections of the plants by an external auditor.

Chairman Tsutomu Une, also in an interview, said the quality-control issues - which largely involved poor documentation of procedures - were an embarassment for the Indian drugmaker.

"This must never happen again," said Une, who has a seat on Daiichi Sankyo's board of directors.

 

RECOMMENDED FOR YOU

Ranbaxy puts biosimilars into gear

RANBAXY-BIOSIMILARS-LAUNCHES:Ranbaxy puts biosimilars into gear

Ranbaxy Laboratories Ltd will launch at least three copies of biotech medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech drugs to remain a serious player in the global generics business, Chief Executive Arun Sawhney said on Tuesday.  July 11, 2012, 3:23 IST

 07 11, 2012, 03:30 IST

 

Laboratories Ltd will launch at least three copies of biotech medicines in India by 2015, mostly to treat cancer, and needs to develop such high-tech drugs to remain a serious player in the global generics business, Chief Executive Arun Sawhney said on Tuesday.

Sawhney said that Ranbaxy, majority-owned by Japanese drugmaker Daiichi Sankyo <4568.T>, will introduce a "biosimilar" cancer treatment in India next year and follow up with at least two other in the same market over the following year or two.

The company's goal is to seek initial approval for all the drugs in India and then pursue approval within four to five years in Europe and the United States.

Like other biotech medicines, biosimilar drugs are made in living cells through a costly and time-consuming process. currently sells only one biosimilar, a copycat form of Amgen Inc's Neupogen, used to prevent infections following chemotherapy. The product is sold in India.

Sawhney said two of Ranbaxy's chief rivals, Israeli drugmaker Teva Pharmaceutical Industries and the Sandoz unit of Swiss drugmaker , already have expertise in biosimilars. hopes to eventually compete with them in the potentially lucrative business, he said.

The biosimilar plans to introduce in India next year, Sawhney said in an interview in New York, has the potential for global annual sales in the hundreds of millions of dollars.

"The attractiveness of biosimilars, regardless of the product, is you'll always have limited competition because of the complexity and the investments required" to make such medicines, he said.

Other drugmakers, including Merck & Co , are racing to develop even though the U.S. Food and Drug Administration has yet to announce formal guidelines for how biosimilar medicines should be tested and marketed. Europe has already released such guidelines.

"Of the top 10 drugs in the world, more than half are biotech drugs and probably seven of the top 10 will be by 2015. That tells us the importance of being present in the biosimilar space," Sawhney said. "If we want to remain a serious (industry) player, inherently we must be competitive."

Sawhney became chief executive in 2010, a year after the FDA forbade shipments to the United States of generic medicines made at two factories in India that were cited for quality-control lapses.

Shipments from the plants resumed in April, after agreed to terms of a consent decree with the FDA. It mandates quality-control inspections of the plants by an external auditor.

Chairman Tsutomu Une, also in an interview, said the quality-control issues - which largely involved poor documentation of procedures - were an embarassment for the Indian drugmaker.

"This must never happen again," said Une, who has a seat on Daiichi Sankyo's board of directors.

 

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard